Feasibility study to inform the design of a randomised controlled trial to eradicate Pseudomonas aeruginosa infection in individuals with Cystic Fibrosis

Trials

Volumn 11, Issue , 2010, Pages

  Hickey, Helen R ^a   Jones, Ashley P ^a   Lenney, Warren ^b   Williamson, Paula R ^a   Smyth, Rosalind L ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b UNIVERSITY HOSPITAL OF NORTH STAFFORDSHIRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CIPROFLOXACIN; COLISTIN; ANTIINFECTIVE AGENT;

ADOLESCENT; ADULT; ARTICLE; BACTERIAL GROWTH; BACTERIUM ISOLATION; CLINICAL PRACTICE; CLINICAL STUDY; CONTROLLED STUDY; CYSTIC FIBROSIS; ERADICATION THERAPY; FEASIBILITY STUDY; HUMAN; INFECTION CONTROL; NEBULIZATION; PARENTAL ATTITUDE; PHYSICIAN ATTITUDE; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; QUESTIONNAIRE; STUDY DESIGN; UNITED KINGDOM; CHILD; COMPARATIVE STUDY; FEMALE; MALE; MICROBIOLOGY; MIDDLE AGED; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PATHOGENICITY; PATIENT SELECTION; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFECTION;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; CHILD; CYSTIC FIBROSIS; FEASIBILITY STUDIES; FEMALE; GREAT BRITAIN; HUMANS; MALE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; PATIENT SELECTION; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; QUESTIONNAIRES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESPIRATORY TRACT INFECTIONS; YOUNG ADULT;

EID: 77949620847     PISSN: 17456215     EISSN: 17456215     Source Type: Journal    
DOI: 10.1186/1745-6215-11-11     Document Type: Article

References (14)

1. FitzSimmons SC. The changing epidemiology of cystic fibrosis. J Pediatr 1993, 122(1):1-9. 10.1016/S0022-3476(05)83478-X, 8419592.
2. Courtney JM, Bradley J, Mccaughan J, O'Connor TM, Shortt C, Bredin CP, Bradbury I, Elborn JS. Predictors of mortality in adults with cystic fibrosis. Pediatr Pulmonol 2007, 42(6):525-32. 10.1002/ppul.20619, 17469153.
3. Lai HJ, Cheng Y, Cho H, Kosorok MR, Farrell PM. Association between initial disease presentation, lung disease outcomes, and survival in patients with cystic fibrosis. Am J Epidemiol 2004, 159(6):537-46. 10.1093/aje/kwh083, 15003957.
4. Frederiksen B, Koch C, Hoiby N. Antibiotic treatment of initial colonisation with Pseudomonas aeruginosa postpones cross infection and prevents deterioration of pulmonary function in cystic fibrosis. Pediatr Pulmonol 1997, 23:330-5. 10.1002/(SICI)1099-0496(199705)23:5<330::AID-PPUL4>3.0.CO;2-O, 9168506.
5. Langton Hewer SC, Smyth AR. Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis. Cochrane Database of Systematic Reviews 2009, 4(7):CD004197. DOI: 10.1002/14651858.CD004197.pub2.
6. UK Cystic Fibrosis Trust Antibiotic Group Antibiotic Treatment for Cystic Fibrosis. 2002, Cystic Fibrosis Trust, Second, UK Cystic Fibrosis Trust Antibiotic Group.
7. Taccetti G, Campana S, Festini F, Mascherini M, Doring G. Early eradication therapy against Pseudomonas aeruginosa in cystic fibrosis patients. Eur Respir J 2005, 26(3):458-61. 10.1183/09031936.05.00009605, 16135728.
8. Cheng K, Smyth RL, Motley J, O'Hea U, Ashby D. Randomized controlled trials in cystic fibrosis (1966-1997) categorized by time, design, and intervention. Pediatr Pulmonol 2000, 29(1):1-7. 10.1002/(SICI)1099-0496(200001)29:1<1::AID-PPUL1>3.0.CO;2-1, 10613779.
9. Cheng K, Preston C, Ashby D, O'Hea U, Smyth RL. Time to publication as full reports of abstracts of randomized controlled trials in cystic fibrosis. Pediatr Pulmonol 1998, 26(2):101-5. 10.1002/(SICI)1099-0496(199808)26:2<101::AID-PPUL5>3.0.CO;2-P, 9727760.
10. Poustie VJ, Russell JE, Watling RM, Ashby D, Smyth RL. Oral protein energy supplements for children with cystic fibrosis: CALICO multicentre randomised controlled trial 4. BMJ 2006, 332(7542):632-6. 10.1136/bmj.38737.600880.AE, 1403226, 16467348.
11. Balfour-Lynn IM, Lees B, Hall P, Phillips G, Khan M, Flather M, Elborn JS, . CF WISE (Withdrawal of Inhaled Steroids Evaluation) Investigators Multicenter randomized controlled trial of withdrawal of inhaled corticosteroids in cystic fibrosis. Am J Respir Crit Care Med 2006, 173(12):1356-62. 10.1164/rccm.200511-1808OC, 16556691, CF WISE (Withdrawal of Inhaled Steroids Evaluation) Investigators.
12. Briggs TA, Bryant M, Smyth RL. Controlled clinical trials in cystic fibrosis--are we doing better? 5. J Cyst Fibros 2006, 5(1):3-8.
13. Smyth RL. Making a difference: the clinical research programme for children. Arch Dis Child 2007, 92(10):835-7. 10.1136/adc.2006.113357, 17895331.
14. Smyth RL. Research with children. Paediatric practice needs better evidence-- gained in collaboration with parents and children. BMJ 2001, 322(7299):1377-8. 10.1136/bmj.322.7299.1377, 1120459, 11397728.